Skip to main content
. 2018 Sep 28;16(10):354. doi: 10.3390/md16100354

Figure 3.

Figure 3

Total proteins from mRET inhibitor-treated C. pyrenoidosa and the control. Lane 1, antimycin A treatment; lane 2, SHAM treatment; lane 3, NaN3 treatment; lane 4, control. Arrows: Representative bands in lanes 1–3 exhibiting significant difference with lane 4. The samples were loaded at the same protein concentration.